SCHEMBL23925202

SCHEMBL23925202

CC(=O)CC/C=C(/C)CC/C=C(\C)CCC=C(C)CO

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
MAPT P10636 2/20 0.50
MEN1 O00255 2/20 0.50
CYP3A4 P08684 2/20 0.50
ALOX15 P16050 2/20 0.50
ALDH1A1 P00352 1/20 0.50
UGT1A1 P22309 1/20 0.50
SQLE Q14534 5/20 0.48
BTN3A1 O00481 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ATM Q13315 1/20 0.47
FNTA P49354 2/20 0.46
FNTB P49356 2/20 0.46
POLB P06746 1/20 0.45
KDM1A O60341 1/20 0.44
ICMT O60725 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11018787 1.00 KMT2A (0.50) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL5373410 1.00 KMT2A (0.50) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL3087751 1.00 KMT2A (0.50) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL11023522 1.00 KMT2A (0.50) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL23925025 1.00 KMT2A (0.50) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL5373407 1.00 KMT2A (0.50) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL23924906 1.00 KMT2A (0.50) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL25220642 1.00 KMT2A (0.50) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL11021028 1.00 KMT2A (0.50) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL28971392 1.00 KMT2A (0.50) KMT2AMAPTMEN1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12584153-B2 Enzyme-mediated process for making Amberketal and Amberketal homologues GIVAUDAN SA (CH) 2026-03-24 US disclosed
EP-4561978-A1 PROCESS Givaudan SA (CH) 2025-06-04 EP disclosed
US-20250027126-A1 IMPROVED METHODS AND ENZYMES GIVAUDAN SA (CH) 2025-01-23 US disclosed
EP-4419700-A1 IMPROVED METHODS AND ENZYMES Givaudan SA (CH) 2024-08-28 EP disclosed
WO-2024023154-A1 PROCESS GIVAUDAN SA (CH) 2024-02-01 WO disclosed
WO-2023067043-A9 IMPROVED METHODS AND ENZYMES GIVAUDAN SA (CH) 2023-06-15 WO disclosed
US-20230175027-A1 ENZYME-MEDIATED PROCESS FOR MAKING AMBERKETAL AND AMBERKETAL HOMOLOGUES GIVAUDAN SA (CH) 2023-06-08 US disclosed
WO-2023067043-A1 IMPROVED METHODS AND ENZYMES GIVAUDAN SA (CH) 2023-04-27 WO disclosed
EP-4136246-A1 ENZYME-MEDIATED PROCESS FOR MAKING AMBERKETAL AND AMBERKETAL HOMOLOGUES Givaudan SA (CH) 2023-02-22 EP disclosed
WO-2021209482-A1 ENZYME-MEDIATED PROCESS FOR MAKING AMBERKETAL AND AMBERKETAL HOMOLOGUES GIVAUDAN SA (CH) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250027126-A1 IMPROVED METHODS AND ENZYMES ASAH1, COASY, SQLE KMT2A 1998/4885MAPT 4288/4885MEN1 2569/4885
US-12584153-B2 Enzyme-mediated process for making Amberketal and Amberketal homologues ALKBH5, AMD1, ALKBH1 KMT2A 863/4885MAPT 4597/4885MEN1 2825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.